Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 94-100
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.94
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.94
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: State of the art
Ramez N Eskander, Robert E Bristow, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Irvine Medical Center, University of California, Irvine, CA 92868, United States
Luca Ansaloni, Federico Coccolini, Department of General and Emergency Surgery, Ospedali Riuniti, 24100 Bergamo, Italy
Author contributions: Eskander RN, Bristow RE, Ansaloni L and Coccolini F contributed equally to the article, with respect to literature review, writing and editing.
Correspondence to: Ramez N Eskander, MD, Clinical Instructor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Irvine Medical Center, University of California, 101 the City Drive South Orange, Irvine, CA 92868, United States. eskander@uci.edu
Telephone: +1-626-6443712 Fax: +1-714-4567754
Received: December 13, 2012
Revised: June 26, 2013
Accepted: August 4, 2013
Published online: November 10, 2013
Processing time: 339 Days and 6.1 Hours
Revised: June 26, 2013
Accepted: August 4, 2013
Published online: November 10, 2013
Processing time: 339 Days and 6.1 Hours
Core Tip
Core tip: Hyperthermic intraperitoneal chemotherapy (HIPEC), when used in combination with successful surgical cytoreduction appears to result in promising oncologic outcomes. We will eagerly await the results of the various phase 3 clinic trials, and until that time advocate the use of cytoreductive surgery + HIPEC in experienced centers under the auspices of appropriate institutional research programs.